

References

- **A.Pupo-Nogueira , R.M. de Oliveira , C.A. Petta , S. Podgaec , Dias J.A. Jr. , M.S. Abrao 2007.** Vascular endothelial growth factor concentrations in the serum and peritoneal fluid of women with endometriosis. *International Journal of Gynecology and Obstetrics* 99, 33–37.
- **American Society for Reproductive Medicine 1997.** Revised American Society for Reproductive Medicine classification of endometriosis: 1996. *Fertil Steril*; 67: 817-21.
- **Ann Hoeben, Bart Landuyt, Martin S. Highley, Hans Wildiers, Allan T. Van 2004.** Vascular Endothelial Growth Factor and Angiogenesis. *Pharmacological Reviews* Vol. 56, No. 4, 549–580.
- **Barbieri RL 1992.** Hormone treatment of endometriosis: the estrogen threshold hypothesis. *Am J Obstet Gynecol*; 166: 740-5.
- **Batzer FR 2006.** GnRH analogs: options for endometriosis associated pain treatment. *J Minim Invasive Gynecol*; 13: 539-45.
- **Bedaiwy M, Casper R 2006.** Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage IV endometriosis patients with chronic pelvic pain. *Fertil Steril*; 86: 220-2.
- **Beksinska ME, Kleinschmidt I, Smit JA, et al., 2007.** Bone mineral density in adolescents using norethisterone enanthate,

- depot-medroxyprogesterone acetate or combined oral contraceptives for contraception. *Contraception*; 75: 438-43.
- **Beksinska ME, Smit JA, Kleinschmidt I, et al., 2005.** Bone mineral density in women aged 40–49 years using depot medroxyprogesterone acetate, norethisterone enanthate or combined oral contraceptives for contraception. *Contraception*; 71: 170-5.
 - **Bergers G, Hanahan D (August 2008).** Modes of resistance to anti-angiogenic therapy. *Nat. Rev. Cancer* 8 (8): 592–603.
 - **Bergqvist A, Theorell T 2001.** Changes in quality of life after hormonal treatment of endometriosis. *Acta Obstet Gynecol Scand*; 80: 628-37.
 - **Brenner RM, Nayak NR, Slayden OD, Critchley HO, Kelly RW 2002.** Premenstrual and menstrual changes in the macaque and human endometrium: relevance to endometriosis. *Ann N Y Acad Sci*; 955:60–74.
 - **Brosens IA, Brosens JJ 2000.** Is laparoscopy the gold standard for the diagnosis of endometriosis? *Eur J Obstet Gynecol Reprod Biol*; 88:117-9.
 - **Chu MC, Zhang X, Gentzschein E, et al., 2007.** Formation of ethinyl estradiol in women during treatment with norethindrone acetate. *J Clin Endocrinol Metab*; 92: 2205-7.
 - **Clark MK, Sowers MR, Nichols S, et al., 2004.** Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. *Fertil Steril*; 82: 1580-6.

- **Coffee AL, Sulak PJ, Kuehl TJ 2007.** Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. *Contraception*; 75: 444-9.
- **Cornillie FJ, Oosterlynck D, Lauweryns J, et al., 1993.** Deeply infiltrating pelvic endometriosis: histology and clinical significance. *Fertil Steril*; 53: 978-83.
- **Crosgnani P, Olive D, Bergqvist A, et al., 2006.** Advances in the management of endometriosis: an update for clinicians. *Hum Reprod Update*; 12: 179-89.
- **Crosgnani PG, Luciano A, Ray A, et al., 2006.** Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. *Hum Reprod*; 21: 248-56.
- **Cundy T, Cornish J, Roberts H, et al., 2002.** Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception. *Am J Obstet Gynecol*; 186: 978-83.
- **Davis L, Kennedy S, Moore J, et al., 2007.** Modern combined oral contraceptives for pain associated with endometriosis. *Cochrane Database Syst Rev*; 3: CD001019.
- **DeMayo FJ, Zhao B, Takamoto N & Tsai SY 2002.** Mechanisms of action of estrogen and progesterone. *Annals of the New York Academy of Sciences*; 955 48–59.
- **Dicker D, Goldman GA, Ashkenazi J, et al., 1990.** The value of pre-treatment with gonadotrophin releasing hormone (GnRH)

analogue in IVF-ET therapy of severe endometriosis. *Hum Reprod*; 5: 418-20.

- **Errica Weir 2001.** The public health tool of endometriosis. *CMAJ*; 164 (8).
- **Ewies AAA 2007.** Mirena: the other side of the story. *BJOG*; 114: 1307-8.
- **Farquhar C 2000.** Endometriosis [review]. *BMJ*; 320:1449-52.
- **Fedele L, Arcaini L, Bianchi S, et al., 1989.** Comparison of cyproterone acetate and danazol in the treatment of pelvic pain associated with endometriosis. *Obstet Gynecol*; 73: 1000-4.
- **Fedele L, Bianchi S, Raffaelli R, et al., 1999.** Comparison of transdermal estradiol and tibolone for the treatment of oophorectomized women with deep residual endometriosis. *Maturitas*; 32: 189-93.
- **Fedele L, Bianchi S, Zanconato G, et al., 2001.** Use of a levonorgestrel- releasing intrauterine device in the treatment of rectovaginal endometriosis. *Fertil Steril*; 75: 485-8.
- **Finas D, Hornung D, Diedrich K, et al., 2006.** Cetrorelix in the treatment of female infertility and endometriosis. *Expert Opin Pharmacother*; 7: 2155-68.
- **Ford J, English J, Miles WA, et al., 2004.** Pain, quality of life and complications following the radical resection of rectovaginal endometriosis. *BJOG*; 111: 353-6.

- **Fujishita A, Hasuo A, Khan KN, Masuzaki H, Nakashima H, Ishimaru T 1999.** Immunohistochemical study of angiogenic factors in endometrium and endometriosis. *Gynecol Obstet Invest*; 48(suppl 1):36–44.
- **Gagne D, Page M, Robitaille G, Hugo P, Gosselin D 2003.** Levels of vascular endothelial growth factor (VEGF) in serum of patients with endometriosis. *Hum Reprod*; 18:1674–80.
- **Gazvani R, Templeton A 2002.** Peritoneal environment, cytokines and angiogenesis in the pathophysiology of endometriosis. *Reproduction*; 123:217–26.
- **Gucer F, Pieber D, Arikan MG 1998.** Malignancy arising in extraovarian endometriosis during estrogen stimulation. *Eur J Gynaecol Oncol*; 19: 39-41.
- **Guillemin R 2005.** Hypothalamic hormones a.k.a. hypothalamic releasing factors. *J Endocrinol*; 184: 11-28.
- **Hanahan K 2002.** Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. *Cell* **86**:353–364.
- **Haney AF, Wild RA 2007.** Options for hormone therapy in women who have had a hysterectomy. *Menopause*; 14: 592-7.
- **Harada T, Momoeda M, Taketani Y, et al., 2008.** Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. *Fertil Steril*; 90: 1583-8.
- **Harrison RF, Barry-Kinsella C 2000.** Efficacy of medroxyprogesterone treatment in infertile women with

endometriosis: a prospective, randomized, placebo-controlled study. *Fertil Steril*; 74: 24-30.

- **Higham JM, O'Brien PM, Shaw RW 1990.** Assessment of menstrual blood loss using a pictorial chart. *Br J Obstet Gynaecol*; 97: 734-9.
- **Houston DE, Noller KL, Melton LJ 3rd, et al., 1987.** Incidence of pelvic endometriosis in Rochester, Minnesota, 1970-1979. *Am J Epidemiol*; 125: 959-69.
- **Huirne JA, Lambalk CB 2001.** Gonadotropin-releasing hormone-receptor antagonists. *Lancet*; 358: 1793-803.
- **Jain S, Dalton ME 1999.** Chocolate cysts from ovarian follicles. *Fertil Steril*; 72: 852-6.
- **Janssens RM, Brus L, Cahill DJ, et al., 2000.** Direct ovarian effects and safety aspects of GnRH agonists and antagonists. *Hum Reprod Update*; 6: 505-18.
- **Jones KD, Owen E, Berresford A, et al., 2002.** Endometrial adenocarcinoma arising from endometriosis of the rectosigmoid colon. *Gynecol Oncol*; 86: 220-2.
- **Kaunitz AM 1994.** Long-acting injectable contraception with depot medroxyprogesterone acetate. *Am J Obstet Gynecol*; 170: 1543-9.
- **Kennedy S 1998.** The genetics of endometriosis. *J Reprod Med*; 43: 263-8.

- **Kennedy S, Bergqvist A, Chapron C, et al., 2005.** ESHRE Special Interest Group for Endometriosis and Endometrium Guideline Development Group. ESHRE guideline for the diagnosis and treatment of endometriosis. *Hum Reprod*; 20: 2698-704.
- **Kerbel RS 2000.** Tumor angiogenesis: past, present and the near future. *Carcinogenesis* **21**:505–515.
- **Kim JG, Suh CS, Kim SH, et al., 2000.** Insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs), and IGFBP-3 protease activity in the peritoneal fluid of patients with and without endometriosis. *Fertil Steril*; 73: 996-1000.
- **Kinkel K, Chapron C, Balleyguier C, et al., 1999.** Magnetic resonance imaging characteristics of deep endometriosis. *Hum Reprod*; 14: 1080-6.
- **Lavery S, Gillmer M 2001.** Malignant transformation of residual endometriosis in women on unopposed oestrogen hormone replacement therapy. *BJOG*; 108: 1106-7.
- **Lindsay PC, Shaw RW, Bennink HJ, et al., 1996.** The effect of add-back treatment with tibolone (Livial) on patients treated with the gonadotropin-releasing hormone agonist triptorelin (Decapeptyl). *Fertil Steril*; 65: 342-8.
- **Liu E, Morimoto M, Kitajima S, et al., (July 2007).** Increased expression of vascular endothelial growth factor in kidney leads to progressive impairment of glomerular functions. *J. Am. Soc. Nephrol*; 18 (7): 2094–104.

- **Liu X, Yuan L, Shen F, et al., 2007.** Patterns of and risk factors for recurrence in women with ovarian endometriomas. *Am J Obstet Gynecol*; 109: 1411-20.
- **Lockhat FB, Emembolu JO, Konje JC 2004.** The evaluation of the effectiveness of an intrauterine-administered progestogen (levonorgestrel) in the symptomatic treatment of endometriosis and in the staging of the disease. *Hum Reprod*; 19: 179-84.
- **Lockhat FB, Emembolu JO, Konje JC 2005.** The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up. *Hum Reprod*; 20: 789-93.
- **Loverro G, Carriero C, Rossi AC, et al., 2008.** A randomized study comparing triptorelin or expectant management following conservative laparoscopic surgery for symptomatic stage III-IV endometriosis. *Eur J Obstet Gynecol Reprod Biol*; 136 (2): 194-8.
- **Marjan Attaran, Tommaso Falcone, Jeffrey Goldberg (August 2002).** Endometriosis: Still tough to diagnose and treat. *Cleveland Clinic Journal Of Medicine* VOL. 69, Number 8.
- **Matalliotakis, I.M., Goumenou, A.G., Koumantakis, G.E., Neonaki, M.A., Koumantakis, E.E., Dionyssopoulou, E., Athanassakis, I. and Vassiliadis, S 2003.** Serum concentrations of growth factors in women with and without endometriosis: the action of anti-endometriosis medicines. *Int. Immunopharmacol.*, 3, 81±89.

- **McLaren J, Prentice A, Charnock-Jones DS, Smith SK 1996.** Vascular endothelial growth factor (VEGF) concentrations are elevated in peritoneal fluid of women with endometriosis. *Hum Reprod*; 11:220–3.
- **Missmer SA, Hankinson SE, Spiegelman D, et al., 2004.** Reproductive history and endometriosis among premenopausal women. *Obstet Gynecol*; 104: 965-74.
- **Modugno F, Ness RB, Allen GO, et al., 2004.** Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. *Am J Obstet Gynecol*; 191: 733-40.
- **Moore C, Kohler G, Muller A 1999.** The treatment of endometriosis with dienogest. *Drugs Today* ; 35 Suppl. C: 41-52
- **Moran C, Alcivia JC, Garcia-Hernandez E, et al., 1996.** Treatment of endometriosis with cyproterone acetate: preliminary report. *Arch Med Res*; 27: 535-8.
- **Muneyyirci-Delale O, Karacan M 1998.** Effect of norethindrone acetate in the treatment of symptomatic endometriosis. *Int J Fertil Womens Med*; 43: 24-7.
- **Nagy JA, Brown LF, Senger DR, Lanir N, van de Water L, Dvorak AM, and Dvorak HF 1989.** Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. *Biochim Biophys Acta* **948**:305–326.

- **Nisolle M, Casanas-Roux F, Donnez J 2000.** Early-stage endometriosis: adhesion and growth of human menstrual endometrium in nude mice. *Fertil Steril*; 74:306–12.
- **Olive D 2004.** Optimizing gonadotropin-releasing hormone agonist therapy in women with endometriosis. *Treat Endocrinol*; 3: 83-9.
- **Omland AK, Tanbo T, Dale PO, et al., 1998.** Artificial insemination by husband in unexplained infertility compared with infertility associated with peritoneal endometriosis. *Hum Reprod*; 13: 2602-5.
- **Pabuccu R, Onalan G, Kaya C 2007.** GnRH agonist and antagonist protocols for stage I-II endometriosis and endometrioma in vitro fertilization/intracytoplasmic sperm injection cycles. *Fertil Steril*; 88: 832-9.
- **Parazzini F, Di Cintio E, Chatenoud L, et al., 2000.** Estroprogestin vs. gonadotropin agonists plus estroprogestin in the treatment of endometriosis-related pelvic pain: a randomized trial. *Eur J Obstet Gynecol Reprod Biol*; 88: 11-4.
- **Petta CA, Ferriani RA, Abrao MS, et al., 2005.** Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH analogue for the treatment of chronic pelvic pain in women with endometriosis. *Hum Reprod*; 20: 1993-8.
- **Pizzo, A., Salmeri, F.M., Ardita, F.V., Sofo, V., Tripepi, M. and Marsico, S. 2002.** Behaviour of cytokine levels in serum and peritoneal fluid of women with endometriosis. *Gynecol. Obstet. Invest.*, 54, 82±87.

- **Prentice A 2001.** Endometriosis. *BMJ*; 323: 93-5.
- **Prentice A, Deary A, Goldbeck-Wood S, et al., 2007.** Gonadotrophin- releasing hormone analogues for pain associated with endometriosis. *Cochrane Database Syst Rev*; 3: CD000346.
- **Ray Garry 2004.** The endometriosis syndromes: a clinical classification in the presence of aetiological confusion and therapeutic anarchy. *Human Reproduction* Vol.19, No.4 pp. 760-768.
- **Riis BJ, Lehmann HJ, Christiansen C 2002.** Norethisterone acetate in combination with estrogen: effects on the skeleton and other organs: a review. *Am J Obstet Gynecol*; 187: 1101-6.
- **Rock JA, Markham SM 1992.** Pathogenesis of endometriosis. *Lancet*; 340: 1264-7.
- **Sallam HN, Garcia-Velasco JA, Dias S, et al., 2006.** Long-term pituitary down regulation before in vitro fertilization (IVF) for women with endometriosis. *Cochrane Database Syst Rev*; 1: CD004635.
- **Schlaff WD, Carson SA, Luciano A, et al., 2006.** Subcutaneous injection of depot medroxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis-associated pain. *Fertil Steril*; 85: 314-25.
- **Shaarawy M, El-Mallah SY, Seoudi S, et al., 2006.** Effect of long-term use of depot medroxyprogesterone acetate as hormonal contraceptive on bone mineral density and biochemical markers of bone remodeling. *Contraception*; 74: 297-302.

- **Shifren JL, Tseng JF, Zaloudek CJ, Ryan IP, Meng YG, Ferrara N, et al., 1996.** Ovarian steroid regulation of vascular endothelial growth factor in the human endometrium: implications for angiogenesis during the menstrual cycle and in the pathogenesis of endometriosis. *J Clin Endocrinol Metab*; 81: 3112–8.
- **Shulman LP, Nelson AL, Darney PD 2004.** Recent developments in hormone delivery system. *Am J Obstet Gynecol*; 190: S39-48.
- **Skegg DCG, Noonan EA, Paul C, et al., 1995.** Depot medroxyprogesterone acetate and breast cancer: a pooled analysis of the World Health Organization and New Zealand Studies. *JAMA*; 273: 799-804.
- **Soliman NF, Hillard TC 2006.** Hormone replacement therapy in women with past history of endometriosis. *Climacteric*; 9: 325-35.
- **Somigliana E, Vercellini P, Vigano P, et al., 2006.** Should endometriomas be treated before IVF-ICSI cycles? *Hum Reprod Update*; 12: 57-64.
- **Struthers RS, Xie Q, Sullivan SK, et al., 2007.** Pharmacological characterization of a novel nonpeptide antagonist of the human gonadotropin-releasing hormone receptor, NBI- 42902. *Endocrinology* ; 148: 857-67
- **Tan XJ, Lang JH, Liu DY, Shen K, Leng JH, Zhu L 2002.** Expression of vascular endothelial growth factor and thrombospondin- mRNA in patients with endometriosis. *Fertil Steril*; 78: 148–53.

- **Tan XJ, Lang JH, Liu DY, Shen K, Leng JH, Zhu L 2002.** Expression of vascular endothelial growth factor and thrombospondin-1 mRNA in patients with endometriosis. *Fertil Steril*; 78: 148–53.
- **Taylor, R.N., Lebovic, D.I. and Mueller, M.D. 2002.** Angiogenic factors in endometriosis. *Ann. NY Acad. Sci.*, 955, 89±100.
- **The American Fertility Society 1985.** Revised American Fertility Society classification of endometriosis. *Fertil Steril*; 43: 351-2.
- **The investigation and management of endometriosis 2000.** Royal College of Obstetricians and Gynaecologists Guideline No. 24. London: RCOG.
- **Tim J. Child and Seang Lin Tan 2001.** Endometriosis Aetiology, Pathogenesis and Treatment. *Drugs*; 61 (12): 1735-1750.
- **Tsuji T, Sasaki Y, Tanaka M, Hanabata N, Hada R, and Munakata A 2002.** Microvessel morphology and vascular endothelial growth factor expression in human colonic carcinoma with or without metastasis. *Lab Investig* **82**:555–562.
- **Tulandi T, editor 1999.** Atlas of laparoscopic and hysteroscopic techniques for the gynecologist. London: WB Saunders.
- **Valle RF 2002.** Endometriosis: current concepts and therapy. *International Journal of Gynaecology and Obstetrics* 78 107–119.
- **Vercellini P, Aimi G, Panazza S, et al., 1999.** A levonorgestrel-releasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis: a pilot study. *Fertil Steril*; 72: 505-8.

- **Vercellini P, De Giorgi O, Mosconi P, et al., 2002.** Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. *Fertil Steril*; 77: 52-61.
- **Vercellini P, De Giorgi O, Oldani S, et al., 1996.** Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. *Am J Obstet Gynecol*; 175: 396-401.
- **Vercellini P, De Giorgi O, Pisacreta A, Pesole AP, Vincentini S, Crosignani PG 2000.** Surgical management of endometriosis. *Baillieres Best Pract Res Clin Obstet Gynaecol*; 14:501-23.
- **Vercellini P, Fedele L, Aimi G, et al., 2006.** Reproductive performance, pain recurrence and disease relapse after conservative surgical treatment for endometriosis: the predictive value of the current system. *Hum Reprod*; 21: 2679-85.
- **Vercellini P, Fedele L, Pietropaolo G, et al., 2003.** Progestogens for endometriosis: forward to the past. *Hum Reprod Up*; 9: 387-96.
- **Vercellini P, Frontino G, De Giorgi O, et al. 2003.** Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhoea that does not respond to a cyclic pill regimen. *Fertil Steril* ; 80: 560-3
- **Vercellini P, Frontino G, De Giorgi O, et al., 2003.** Comparison of a levonorgestrel-releasing intrauterine device versus expectant management after conservative surgery for symptomatic endometriosis: a pilot study. *Fertil Steril*; 80: 305-9

- **Vercellini P, Pietropaolo G, De Giorgi O, et al., 2005.** Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate. *Fertil Steril*; 84: 1375-87.
- **Vercellini P, Somigliana E, Daguati R, et al., 2008.** Postoperative oral contraceptive exposure and risk of endometrioma recurrence. *Am J Obstet Gynecol*; 198: 504e1-5.
- **Vercellini P, Somigliana E, Vigano` P, et al., 2008.** Endometriosis: current and future medical therapies. *Best Pract Res Clin Obstet Gynaecol*; 22: 275-306.
- **Vercellini P, Trespidi L, Colombo A, et al., 1993.** A gonadotropin releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. *Fertil Steril*; 60: 75-9.
- **Vercellini P, Vigano` P, Somigliana E 2005.** The role of the levonorgestrel-releasing intrauterine device in the management of symptomatic endometriosis. *Curr Opin Obstet Gynecol*; 17: 359-65.
- **Vigano` P, Somigliana E, Parazzini F, et al., 2007.** Bias versus causality: interpreting recent evidence of association between endometriosis and ovarian cancer. *Fertil Steril*; 88: 588-93.
- **Vinatier D, Orazi G, Cosson M & Dufor P 2001.** Theories of endometriosis. *European Journal of Obstetrics, Gynecology, and Reproductive Biology*; 96 21–34.

- **Waller KG, Shaw RW 1993.** Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long-term follow-up. *Fertil Steril*; 59: 511-5.
- **Witz CA, Thomas MR, Montoya-Rodriguez IA, Nadir AS, Centonze VE & Schenken RS 2001.** Short-term culture of peritoneum explants confirms attachment of endometrium to intact peritoneal mesothelium. *Fertility and Sterility*; 75 385–390.
- **Yap C, Furness S, Farquhar C 2004.** Pre and post operative medical therapy for endometriosis surgery. *Cochrane Database Syst Rev*; 3: CD003678.
- **Zanetta GM, Webb MJ, Li H, et al., 2000.** Hyperestrogenism: a relevant risk factor for the development of cancer from endometriosis. *Gynecol Oncol*; 79: 18-22.
- **Zupi E, Marconi D, Sbracia M, et al., 2004.** Add-back therapy in the treatment of endometriosis-associated pain. *Fertil Steril* 2004; 82: 1303-8 99. Schindler AE. Gonadotropin-releasing hormone agonists for prevention of postoperative adhesions: an overview. *Gynecol Endocrinol*; 19: 51-5.